Trials / Completed
CompletedNCT00439881
A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose
A Study to Assess the Safety and Tolerability of SB-681323 Administered Via the Intravenous Route
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 25 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
SB-681323 inhibits the action of an enzyme which is known to contribute to the inflammation seen in such conditions as Chronic Obstructive Pulmonary Disease and Rheumatoid Arthritis. This study will explore the safety of this drug and its blood levels when given in intravenous form to healthy human volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-681323 |
Timeline
- Start date
- 2006-10-01
- First posted
- 2007-02-26
- Last updated
- 2012-06-04
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00439881. Inclusion in this directory is not an endorsement.